# Ivabradine

## Coralan 5mg

##### 臨採

| 藥品代碼   | OCOR5                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Heart failure: Reduce the risk of hospitalization for worsening heart failure in patients with stable， symptomatic chronic heart failure with left ventricular ejection fraction ?35%， who are in sinus rhythm with resting heart rate ?70 beats per minute (bpm) and either are on maximally tolerated doses of beta blockers or have a contraindication to beta-blocker use.          |
| 用法用量   | Initial， 5 mg orally twice daily with food; after 2 weeks， adjust based on heart rate; for resting rate greater than 60 beats per minute (bpm)， increase dose by 2.5 mg twice daily; for 50 to 60 bpm， continue current dose; for less than 50 bpm or for signs or symptoms of bradycardia， decrease dose by 2.5 mg twice daily; Maximum dose: 7.5 mg twice daily.                   |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                              |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                              |
| 禁忌       | Acute decompensated heart failure; blood pressure <90/50 mm Hg; sick sinus syndrome， sinoatrial block， or third-degree AV block (unless a functioning demand pacemaker is present); resting heart rate <60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence (heart rate maintained exclusively by the pacemaker); concomitant use with strong CYP3A4 inhibitors. |
| 副作用     | Cardiovascular: Bradycardia (6% to 10%)， hypertension (9%)， atrial fibrillation (5% to 8%)， heart block， sinoatrial arrest Central nervous system: Phosphene (3%) <1% (Limited to important or life-threatening): Angioedema， diplopia， erythema， hypotension， pruritus， skin rash， syncope， urticaria， vertigo， visual impairment.                                          |
| 孕期建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                        |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                      |

